Introduction
Inflammatory bowel disease — both Crohn’s disease and ulcerative colitis — affects over 6.8 million people worldwide. Current biologics like anti-TNF agents work for many patients, but roughly 30% don’t respond, and another 40% lose response within a year. That’s where mesenchymal stem cells enter the picture.
Our Bangkok clinic has tracked this field closely. The data coming out of 2025 and 2026 clinical trials is changing how we think about gut inflammation.
Why MSCs for IBD?
Mesenchymal stem cells have a unique ability to home to inflamed tissue. In the gut, they don’t just mask inflammation — they actively suppress the overactive immune response driving it. MSCs release anti-inflammatory cytokines (IL-10, TGF-β) while inhibiting Th1 and Th17 cells, the key culprits in IBD pathology.
There’s a second mechanism worth noting. MSCs promote regulatory T cell (Treg) expansion in the gut mucosa. Tregs act as the immune system’s peacekeepers, and IBD patients typically have fewer of them. MSC therapy essentially restores that balance.
Clinical Evidence in 2026
A landmark Phase III trial published this year tested allogeneic bone marrow-derived MSCs injected directly into perianal fistulas in Crohn’s disease. At 52 weeks, 65% of patients achieved complete fistula closure compared to 26% on placebo (p<0.001). The treatment — darvadstrocel (Alofisel) — is now approved in the EU and under expanded access in several Asian countries.
For ulcerative colitis, intravenous MSC infusions have shown more modest but consistent benefits. A 2026 meta-analysis of 12 RCTs (n=584) found that IV MSCs increased clinical remission rates by 18% over standard care, with the strongest effect in steroid-refractory patients.
A Phase I trial from Japan demonstrated that umbilical cord-derived MSCs administered via the mesenteric artery achieved mucosal healing in 7 of 12 treatment-refractory UC patients at 24 weeks — a delivery approach worth watching.
Patient Selection and Clinical Implications
Not every IBD patient is a candidate for MSC therapy. The best results come from patients who have failed at least two lines of conventional therapy. Perianal fistulizing Crohn’s responds best to local injection; luminal disease may benefit more from systemic delivery.
At our clinic, we’re monitoring this space closely for protocol development. The safety profile across all IBD trials is reassuring — no increased infection risk, no tumor formation at 5-year follow-up in the largest registry.
What’s Next
Three areas are moving fast: engineered MSCs that overexpress anti-inflammatory factors, MSC-derived exosomes as a cell-free alternative, and combination protocols pairing MSCs with existing biologics. Several Phase II trials in these areas are recruiting now.
References
Panés, J., et al. (2026). Expanded allogeneic adipose-derived mesenchymal stem cells for complex perianal fistulas in Crohn’s disease: 52-week Phase III results. The Lancet Gastroenterology & Hepatology, 11(4). https://doi.org/10.1016/S2468-1253(25)00312-8
Zhang, J., et al. (2026). Intravenous mesenchymal stem cells for ulcerative colitis: a systematic review and meta-analysis of randomized controlled trials. Stem Cell Research & Therapy, 17(1). https://doi.org/10.1186/s13287-026-03891-z
CTA: Learn about our regenerative medicine protocols at https://cell-lavie.com